ResearcherKarolinska InstitutetNo recent work listed

Samir EL Andaloussi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4468-9113; OpenAlex author ID A5059897226. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 1 paper

Papers 1

Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. Last author DOI 10.1002/jev2.12142 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Carlos Fernández Moro · 1 shared paper, 2021 · strength 0.14
- Paper Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. DOI 10.1002/jev2.12142 ↗
Daniel W. Hagey · 1 shared paper, 2021 · strength 0.14
- Paper Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. DOI 10.1002/jev2.12142 ↗
Maximilian Kordes · 1 shared paper, 2021 · strength 0.14
- Paper Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. DOI 10.1002/jev2.12142 ↗
Metoboroghene Oluwaseyi Mowoe · 1 shared paper, 2021 · strength 0.14
- Paper Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. DOI 10.1002/jev2.12142 ↗
Matthias J. Löhr · 1 shared paper, 2021 · strength 0.14
- Paper Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. DOI 10.1002/jev2.12142 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.